Breaking News Instant updates and real-time market news.

CVS

CVS Health

$55.28

-0.29 (-0.52%)

, UNH

UnitedHealth

$247.81

0.82 (0.33%)

07:01
07/09/19
07/09
07:01
07/09/19
07:01

Affordable Care Act reversal faces federal appeals court, New York Times reports

A federal appeals court panel will hear arguments to decide whether a federal judge in Texas was right in reversing the Affordable Care Act, a case with health insurance stakes for millions as well as political consequences for President Donald Trump and other candidates in the 2020 elections, Abby Goodnough of the New York Times reported. The reversal would threaten insurance protections for Americans with pre-existing medical conditions along with various other changes the law has made since its enactment in 2010. The case was filed by a group of Republican governors and attorneys general against the federal government, but the Trump administration declined to defend the entire law in court and said it agreed with the ruling that the requirement for people to purchase insurance was unconstitutional. Now, a group of 21 states with Democratic attorneys general will defend the law, along with the House of Representatives, which entered the case after Democrats won control. Publicly traded companies in the health insurance space include CVS Health's Aetna (CVS), Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG). Publicly traded hospital companies include Community Health (CYH), HCA Healthcare (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS). Reference Link

CVS

CVS Health

$55.28

-0.29 (-0.52%)

UNH

UnitedHealth

$247.81

0.82 (0.33%)

MOH

Molina Healthcare

$139.98

-3.455 (-2.41%)

CI

Cigna

$161.67

-1.755 (-1.07%)

ANTM

Anthem

$284.60

0.5 (0.18%)

HNT

Health Net

$0.00

(0.00%)

CNC

Centene

$51.27

-0.21 (-0.41%)

HUM

Humana

$264.11

-0.57 (-0.22%)

WCG

WellCare

$281.42

-1.075 (-0.38%)

CYH

Community Health

$2.80

-0.03 (-1.06%)

HCA

HCA Healthcare

$137.34

-1.18 (-0.85%)

LPNT

LifePoint

$0.00

(0.00%)

THC

Tenet

$18.95

-0.38 (-1.97%)

UHS

Universal Health

$131.69

0.32 (0.24%)

  • 18

    Jul

  • 23

    Jul

  • 24

    Jul

  • 26

    Jul

  • 30

    Jul

  • 31

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 09

    Sep

  • 13

    Nov

CVS CVS Health
$55.28

-0.29 (-0.52%)

06/05/19
STPT
06/05/19
UPGRADE
STPT
Buy
CVS Health upgraded to Buy from Hold at Standpoint Research
06/25/19
TIGR
06/25/19
NO CHANGE
TIGR
Tigress Financial sees 'significant upside' in CVS Health
Tigress Financial analyst Ivan Feinseth reiterated a Buy rating on CVS Health, citing the ongoing strength in Pharmacy Services, as well as Retail/LTC growth that continues to drive accelerating business performance. Feinseth sees significant upside in the shares and continues to recommend purchase.
06/20/19
JEFF
06/20/19
NO CHANGE
JEFF
Amazon's PillPack looking to bypass PBMs, says Jefferies
Jefferies analyst Brian Tanquilut says his review of documents related to a case filed by CVS Health (CVS), which seeks to prevent a former CVS executive from joining PillPack, shows that Amazon.com (AMZN) is seeking to develop a service offering that would bypass pharmacy benefit managers and contract directly with payors. While it is difficult to predict the success of PillPack's efforts to bypass existing prescription payment structures, the court disclosure is a potential negative for PBMs like CVS Health, UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI), Tanquilut tells investors in a research note.
06/18/19
JEFF
06/18/19
NO CHANGE
Target $58
JEFF
Buy
CVS Health share upside limited on lack of catalysts, says Jefferies
Jefferies analyst Brian Tanquilut believes the "muted" reaction to CVS Health's recent articulation of its planned strategic moves and issuance of guidance thru 2022 underscore the "show-me stance" investors continue to take on the name. The analyst does not see any meaningful near-term catalysts that could drive "significant" stock upside over the next 12 months. That said, the stock's downside is "limited by a discounted valuation," Tanquilut tells investors in a research note. He keeps raised his price target for CVS Health to $58 from $57 and keeps a Hold rating on the name.
UNH UnitedHealth
$247.81

0.82 (0.33%)

07/08/19
BOFA
07/08/19
NO CHANGE
Target $75
BOFA
Neutral
Inspire Medical price target raised to $75 from $65 at BofA/Merrill
BofA/Merrill analyst Bob Hopkins raised his price target for Inspire Medical (INSP) to $75 from $65 after the company announced that United Healthcare (UNH) will provide coverage for Inspire's obstructive sleep apnea therapy as of August 1. In a research note to investors, Hopkins, who maintains a Neutral rating on Inspire, says it takes about 2-4 months for a patient insured by United to work their way through the prior-authorization, but Inspire now estimates that it will take just five days to get approval if a patient meats the restrictions set by United. Hopkins sees potential upside to Street numbers later in 2019 and 2022, but believes his positive outlook is largely reflected in the current stock price.
06/25/19
SBSH
06/25/19
NO CHANGE
SBSH
Molina, Centene have most at stake from Texas Medicaid awards, says Citi
Citi analyst Ralph Giacobbe noted that Texas' "highly anticipated" STAR+PLUS contract for the states' higher acuity Medicaid members is expected to be awarded this Friday, June 28. Among the incumbents in the state, Molina (MOH) and Centene (CNC) have the most at stake, as their respective STAR+PLUS earnings contribute about 7% and 2%, respectively, of his and consensus estimates, Giacobbe tells investors. He estimates that the other incumbents - Anthem (ANTM), Cigna (CI) and UnitedHealth (UNH) - have 1% or less of their earnings at stake, adding that investor expectations are for the incumbents to largely retain business.
06/24/19
ADAM
06/24/19
NO CHANGE
Target $39
ADAM
Buy
HMS Holdings' recent weakness overdone, says Canaccord
Canaccord analyst Richard Close said he believes the recent weakness in HMS Holdings (HMSY) shares is overdone. The weakness was attributed to reports UnitedHealth (UNH) will be buying Equian, a payment integrity services provider. The analyst believes the pullback was based on fears of increased competition and potential risk that HMS will lose UnitedHealth as a customer. He said although both provide integrity services to healthcare, Equian does not provide COB services, which accounted for 66.4% of HMS's revenue. As a result, he does not believe this transaction should raise any concerns. Close reiterated his Buy rating and $39 price target on HMS Holdings shares.
06/21/19
CANT
06/21/19
NO CHANGE
CANT
Overweight
HMS Holdings selloff on Equian deal report overdone, says Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper noted HMS Holdings (HMSY) shares are lower, which he believes is due to media reports that UnitedHealth (UNH) will acquire privately-held Equian, which is focused primarily on payment integrity. Halper notes that payment integrity accounts for about 19% of HMS' total revenue and said any potential transaction could result in health plans switching from Equian to HMS over time. The analyst, who views the selloff as overdone, keeps an Overweight rating on HMS Holdings shares.
MOH Molina Healthcare
$139.98

-3.455 (-2.41%)

06/03/19
BMOC
06/03/19
UPGRADE
Target $200
BMOC
Outperform
Molina Healthcare upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Matt Borsch upgraded Molina Healthcare to Outperform from Market Perform and raised his price target for the shares to $200 from $154. The analyst says the company's 2019 annual investor day gave him higher confidence in the sustainability of its turnaround and better visibility on a "strong" multi-year growth outlook. Molina again emphasized cost efficiency as the key factor in Medicaid Managed Care, and made a "compelling case" for its retention of current contracts affording the opportunity to expand in those markets with further penetration, Borsch tells investors in a research note.
05/31/19
05/31/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Canada Goose (GOOS) upgraded to Buy from Neutral at Goldman Sach with analyst Alexandra Walvis saying she believes the company's fundamentals are "still strong" and the weakness in Q4 was driven in part by strategic changes. 2. Kraft Heinz (KHC) upgraded to Neutral from Underweight at Piper Jaffray with analyst Michael Lavery saying he believes the risks appear to be reflected in the stock's current valuation. 3. Molina Healthcare (MOH) upgraded to Outperform from Market Perform at Wells Fargo with analyst Peter Costa saying management highlighted the long-term sustainability of margins and growth at analyst day, which he thinks should be attainable if Molina can avoid losing ground in upcoming contract rebids. 4. Uber (UBER) upgraded to Overweight from Neutral at Atlantic Equities with analyst James Cordwell saying the ridehailing competitive environment is becoming "increasingly benign" while Uber shares have become more attractively valued. 5. Century Communities (CCS) upgraded to Outperform from Neutral at Wedbush with analyst Jay McCanless saying that based on the firm's recent management meetings, he estimates 85% of the company's collective business is targeted to affordable price points suggesting the company should be well positioned to meet that demand. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/31/19
WELS
05/31/19
UPGRADE
Target $177
WELS
Outperform
Molina Healthcare upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Peter Costa upgraded Molina Healthcare to Outperform from Market Perform and raised his price target to $177 from $139 following the company's analyst day, saying management management highlighted the long-term sustainability of margins and growth which Costa thinks should be attainable if Molina can avoid losing ground in upcoming contract rebids, including Texas, and if it can push its in-market growth strategy at the expense of its managed care competitors. While some found the high margin guidance to be a concern, Costa tells investors in a research note that he believes the low new business win guidance of $1.5B-2.B over 3-5 years to be supportive of the long-term Medicaid after-tax margin guide of 2.8%-3.2%.
CI Cigna
$161.67

-1.755 (-1.07%)

06/03/19
SBSH
06/03/19
NO CHANGE
Target $203
SBSH
Buy
Cigna price target lowered to $203 from $228 at Citi
Citi analyst Ralph Giacobbe lowered his price target for Cigna to $203 from $228 to reflect the recent "re-rating" of the managed care group. Cigna is now a "show me" story that will take some time, Giacobbe tells investors in a research note. The analyst, however, remains bullish on the shares following the company's analyst day and he keeps a Buy rating on the name.
05/16/19
COWN
05/16/19
NO CHANGE
COWN
Move lower in managed care stocks appears overdone, says Cowen
Cowen analyst Charles Rhyee lowered his target multiple for the managed care group slightly from recent historical levels, but said he believes the recent weakness in the space on concerns around "Medicare for All," the rebate rule and the Texas ACA decision appears overdone. The discount for managed care stocks relative to the broader market has risen to a multi-year high, but he argues that underlying market fundamentals are stronger than in the pre-ACA era and Rhyee contends that there is "still plenty of growth left" in the managed care space, particularly in government-sponsored business. Stocks in the group include Anthem (ANTM), Cigna (CI), Centene (CNC), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
ANTM Anthem
$284.60

0.5 (0.18%)

05/10/19
05/10/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. 3D Systems (DDD) upgraded to Neutral from Underweight at JPMorgan with analyst Paul Coster noting the stock is down 25% this week after posting "lackluster" Q1 results. 2. Jones Lang LaSalle (JLL) upgraded to Buy from Neutral at Goldman Sachs with analyst Andrew Rosivach saying the company's earnings declined in Q1 due to tough comps, but this should reverse quickly. 3. Ford (F) upgraded to Buy from Neutral at BofA/Merrill with analyst John Murphy stating the company's earnings are starting to hit a "sustainable inflection" due to favorable product cadence in the North America market and its restructuring efforts. 4. Whirlpool (WHR) upgraded to Buy from Neutral at Longbow with analyst David MacGregor seeing earnings upside from better than expected North American margin performance, a "gradually improving" environment in the EMEA and a favorable cyclical turn in Latin America. 5. Anthem (ANTM), Centene (CNC), and UnitedHealth (UNH) upgraded to Buy from Neutral at Citi with analyst Ralph Giacobbe the magnitude of the selloff in managed care stocks on fears of Medicare for All has been "extreme and overdone". This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
HNT Health Net
$0.00

(0.00%)

04/17/19
SPHN
04/17/19
NO CHANGE
SPHN
Issues facing healthcare sector now 'modest' compared to 2008-10, says Stephens
Stephens analyst Scott Fidel noted that the managed care group has sharply underperformed the S&P 500 over the last month amid "political rhetoric" around point-of-sale drug rebates and Medicare for all policy proposals, though he believes the issues facing the sector right now "seem modest in comparison" to the "dark days of 2008-2010." While recent Medicare for all proposals have rattled investors, "they will face enormous uphill battles," Fidel tells investors. Hospital stocks have outperformed MCOs year-to-date, but the group declined about 9% yesterday and underperformed the MCO group, which Fidel attributes to acknowledgement by industry bellwether UnitedHealth (UNH) of the significant disruptive nature of Medicare for all, which may have sparked additional fears, as well as one less calendar day being called out by UnitedHealth as benefiting Q1 MLRs and Johnson & Johnson's (JNJ) earnings call commentary on declining sequential hospital admissions from Q4. Publicly traded companies in the hospital space include Community Health (CYH), HCA Healthcare (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS). Publicly traded companies in the managed care space include Anthem (ANTM), CVS Health (CVS), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
CNC Centene
$51.27

-0.21 (-0.41%)

06/17/19
06/17/19
NO CHANGE

Centene growth undervalued, political risks overdone, says Piper Jaffray
Centene's valuation multiple has compressed from 17 times to 11 times on healthcare reform risk that has little chance of coming to fruition, Piper Jaffray analyst Sarah James tells investors in a research note. The analyst believes the core Centene business has potential for long-term annual earnings growth in the 20% range. She believes the company's growth is being undervalued while political risks are overdone. The analyst calls Centene a top pick and keeps an Overweight rating on the name with an $80 price target.
06/03/19
CANT
06/03/19
NO CHANGE
Target $83
CANT
Overweight
Centene weakness due to Humana disclosure 'overdone,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper notes that Humana (HUM) released an 8-K filing confirming it will not make a proposal to acquire Centene (CNC). With speculation around Humana's involvement casting doubt on Centene's pending merger with WellCare (WCG), the analyst says the news increases his confidence that the merger will be completed by the third quarter of 2020, and continues to believe that the company's merger with WellCare makes sense and should create significant value. Halper expects Centene-WellCare will have to divest certain Medicaid assets given the overlap in some states, but he believes that the acquisition will ultimately be completed by the company's estimated timeline. The analyst has an Overweight rating and $83 price target on Centene's shares.
06/03/19
BMOC
06/03/19
DOWNGRADE
Target $304
BMOC
Market Perform
WellCare downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Matt Borsch downgraded WellCare Health Plans (WCG) to Market Perform from Outperform with an unchanged price target of $304. The analyst sees Centene (CNC) as the better stock to own ahead of the pending merger. There is also the possibility of deal failure, which would leave a standalone investment in WellCare that would probably include less takeout premium than prevailed pre-merger, Borsch tells investors in a research note.
HUM Humana
$264.11

-0.57 (-0.22%)

05/07/19
SBSH
05/07/19
NO CHANGE
SBSH
Citi sees low likelihood of Centene walking from WellCare deal
Amid reports suggesting shareholders could challenge Centene's (CNC) acquisition of WellCare (WCG), and Humana (HUM) possibly being interested in a takeover of Centene if the WellCare deal was dropped, Citi analyst Ralph Giacobbe says he's be surprised to see the deal unravel. Further, he'd be equally surprised to see Humana come over the top for Centene after its Medicaid win in Florida and recent commentary citing optimism in its organic direction. That said, there is a scarcity of Medicaid assets, and Humana has discussed its interest in dual and other higher acuity Medicaid populations, Giacobbe tells investors in a research note. Nonetheless, the analyst ultimately sees a low likelihood of Centene walking from the WellCare deal.
05/10/19
05/10/19
UPGRADE

Citi upgrades Anthem, Centene, UnitedHealth to Buy after 'extreme' selloff
Citi analyst Ralph Giacobbe upgraded Anthem (ANTM), Centene (CNC), and UnitedHealth (UNH) to Buy from Neutral while maintaining Buy ratings on Cigna (CI) and Humana (HUM). The magnitude of the selloff in managed care stocks on fears of Medicare for All has been "extreme and overdone," Giacobbe tells investors in a research note. The analyst sees favorable risk/rewards in the sector and does not subscribe to the view of a continued "overhang" and "uncertainty." Instead, Giacobbe expects a share recovery as "more realistic views prevail and investors become more numb to the low-likelihood headlines and political rhetoric of single payor."
WCG WellCare
$281.42

-1.075 (-0.38%)

CYH Community Health
$2.80

-0.03 (-1.06%)

11/15/18
UBSW
11/15/18
INITIATION
UBSW
HCA Healthcare, Encompass Health, Universal Health initiated with Buy at UBS
UBS analyst Whit Mayo launched coverage of Healthcare Facilities with a broader research note titled "Navigating an Evolving Landscape - Who Will Be Left?". The analyst is most bullish on stocks that "discount the perceived secular sector headwinds" such as Buy-rated HCA Healthcare (HCA), Encompass Health (EHC), and Universal Health (UHS), adding that investors also under-appreciate the accelerating free-cash flow profiles of these companies. Mayo differentiates HCA Healthcare based on its 0% correlation in national hospital utilization trends against public results. The analyst is also bullish on LHC Group (LHCG), stating that its same-property admission growth projections are higher than the rest. Mayo rates Community Health Systems (CYH), DaVita (DVA), and Mednax (MD) at a Sell with a bearish view of dialysis, births, and inpatient surgery end-markets. The analyst sees Community Health Systems same-property volume trend at a relatively low rate. Mayo also gives Acadia (ACHC), Amedisys (AMED), Surgery Partners (SGRY), and Tenet (THC) a Neutral rating as part of this research note based on their relative valuation as a factor of same-property volume growth.
11/15/18
UBSW
11/15/18
INITIATION
Target $2
UBSW
Sell
Community Health initiated with a Sell at UBS
UBS analyst Whit Mayo initiated Community Health with a Sell rating and a price target of $2.
12/28/18
PIPR
12/28/18
NO CHANGE
PIPR
Piper says buy Centene, sell Community Health if recession were to occur
After performing a recession risk/reward for Hospitals and Managed Care Organizations, Piper Jaffray analyst Sarah James recommends buying Centene (CNC) and selling Community Health Systems (CYH) if a recession were to occur. The analyst says that with some economists calling for a recession in 2019, she dug into the potential impacts across the hospital and insurance sector. For hospitals, consumer surveys point to economic outlook impacting decisions to receive services, James tells investors in a research note. On the other hand, insurers are a "natural defensive sector in a recession," adds the analyst. As such, in a recession James would be adding exposure to insurers and lightening hospitals.
HCA HCA Healthcare
$137.34

-1.18 (-0.85%)

04/17/19
JEFF
04/17/19
NO CHANGE
Target $158
JEFF
Buy
HCA Healthcare oversold on Medicare-For-All 'noise,' says Jefferies
Jefferies analyst Brian Tanquilut says HCA Healthcare shares are now oversold amid the Medicare-For-All "noise." The analyst expects volatility in the stocks of healthcare providers before the November 2020 elections, but he believes the emergence of Medicare for All "as an early hot topic has brought volatility/noise prematurely." HCA is now oversold based on a valuation analysis that looks at previous election cycles, especially since Medicare-For-All does not pose existential risk to the hospitals, Tanquilut tells investors in a research note. As currently proposed, Medicare-For-All will most likely reduce the need for managed care companies, but the need for healthcare providers does not go away, as the government will need hospitals, physician practices, and other providers to remain viable to protect access to care, says the analyst. He keeps a Buy rating on HCA Healthcare with a $158 price target.
04/23/19
RAJA
04/23/19
UPGRADE
RAJA
Outperform
HCA Healthcare upgraded to Outperform from Market Perform at Raymond James
04/23/19
RAJA
04/23/19
UPGRADE
Target $135
RAJA
Outperform
Raymond James ups HCA to Outperform, sees less than 1% odds for Medicare for All
As previously reported, Raymond James analyst John Ransom upgraded HCA Healthcare to Outperform from Market Perform, stating that "the recent selloff in all things healthcare" sparked by "Medicare for All" worries has driven the stock down 12% even though he sees "less than a 1% chance" of such legislation passing. HCA's business continues to skew towards higher value assets and a better mix of revenue trends from non-hospital sources should yield a higher long-term multiple, contends Ransom, who set a $135 price target on HCA shares.
LPNT LifePoint
$0.00

(0.00%)

07/24/18
FBCO
07/24/18
NO CHANGE
Target $65
FBCO
Neutral
LifePoint price target raised to $65 from $58 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for LifePoint (LPNT) to $65 from $58 to reflect deal price after the company agreed to be acquired by Apollo Global (APO) affiliates for $65 per share. The analyst reiterates a Neutral rating on LifePoint shares.
11/07/18
MSCO
11/07/18
NO CHANGE
MSCO
Split Congress 'best outcome' for MCOs and hospitals, says Morgan Stanley
Morgan Stanley analyst Zack Sopcak contends that the Democratic party retaking the majority in the House of Representatives and Republicans retaining the Senate is the "best outcome" for Managed Care Organizations and hospitals, stating that he now sees another attempt at a repeal/replace of the Affordable Care Act as "off the table." The split Congress could also lower the volume on the "Medicare for All" debate given a lack of mandate from either the Democratic or Republican party, Sopcak tells investors. The election results remove a key overhang for Centene (CNC) and Molina (MOH), which he views as most exposed to the ACA marketplace, and to a lesser extent the hospitals, Sopcak added. With ACA repeal/replace off the table, and given the longer term potential upside from Medicaid expansion in Utah and Idaho as expansion ballot initiatives appear to be passing in both states, Sopcak said Molina is emerging as his top pick in the space heading into the final weeks of 2018. Publicly traded hospital companies include Community Health (CYH), HCA Healthcare (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS).
07/24/18
BMOC
07/24/18
NO CHANGE
Target $62
BMOC
Market Perform
LifePoint price target raised to $62 from $51 at BMO Capital
BMO Capital analyst Matt Borsch raised his price target on LifePoint (LPNT) to $62 and kept his Market Perform rating after the proposed transaction for the company to be taken private by the Apollo Global (APO) affiliate RCCH HealthCare Partners at $65 per share. The analyst says his price target reflects the acquisition price blended with some uncertainty regarding the deal, even as he views the terms of the offer as attractive to LifePoint shareholders against the"backdrop of reimbursement and volume pressures that challenge acute care hospitals".
THC Tenet
$18.95

-0.38 (-1.97%)

01/14/19
SPHN
01/14/19
INITIATION
Target $23
SPHN
Equal Weight
Tenet initiated with an Equal Weight at Stephens
Stephens analyst Scott Fidel initiated coverage of 11 Managed Care and Healthcare Facilities stocks, telling investors that overall he is constructive on managed care and selective on hospitals. He started Tenet with an Equal Weight rating and $23 price target, stating that the market's increased volatility could further complicate its efforts to sell Conifer at an attractive valuation. The persistent underperformance of the hospital segment and ongoing divestiture program make it hard to forecast more than low-single digit annual revenue and EBITDA growth, said Fidel.
05/01/19
RHCO
05/01/19
NO CHANGE
Target $27
RHCO
Hold
Tenet price target lowered to $27 from $34 at SunTrust
SunTrust analyst David MacDonald lowered his price target on Tenet to $27 to reflect lower market multiples in the industry. The analyst also keeps his Hold rating on the stock, saying that while the company's Q1 results saw solid volume trends and progress on the management's efficiency initiatives, he sees "continued operational execution and free cash flow generation" as key.
02/27/19
RAJA
02/27/19
NO CHANGE
Target $47
RAJA
Outperform
Tenet price target raised to $47 from $37 at Raymond James
UHS Universal Health
$131.69

0.32 (0.24%)

03/05/19
BMOC
03/05/19
NO CHANGE
Target $146
BMOC
Market Perform
Universal Health price target raised to $146 from $130 at BMO Capital
BMO Capital analyst Matt Borsch raised his price target on Universal Health to $146, citing its above-consensus outlook for 2019 announced last week. The analyst states that while the company remains "reliant on continued acute-care strength", the forecast has given him a better "view of expectations now that management has backed away from promises of near-term improvement in the behavioral side, which should strengthen its credibility." Borsch is keeping his Market Perform rating on Universal Health however, noting that its current valuation of enterprise value to EBITDA at 9.1-times is "fair" and implies only modest stock price upside.
04/29/19
BMOC
04/29/19
NO CHANGE
Target $138
BMOC
Market Perform
Universal Health price target lowered to $138 from $146 at BMO Capital
BMO Capital analyst Matt Borsch lowered his price target on Universal Health to $138 and kept his Market Perform rating after its Q1 earnings miss, saying the results now imply reduced probability for the company to be able to achieve the high end of its FY19 EBITDA target range. The analyst notes that while wage pressures have continued in the quarter, Q1 underperformance was also driven by "lower-acuity volume mix on the acute-care side of the business that weakened the impact from strong volumes."
06/07/19
UBSW
06/07/19
NO CHANGE
Target $151
UBSW
Buy
Universal Health price target lowered to $151 from $161 at UBS
UBS analyst Whit Mayo lowered his price target on Universal Health to $151 but kept his Buy rating on the shares after meeting with its CFO. The analyst notes that he is "struggling" to assess the company's potential for 2019, but the commentary from the management was "broadly positive", maintaining its stance that "stronger medical and weaker surgical trends" reported in Q1 were "transitory", with recent capital projects making the targets for the year achievable.

TODAY'S FREE FLY STORIES

MSFT

Microsoft

$136.29

0.06 (0.04%)

17:50
07/18/19
07/18
17:50
07/18/19
17:50
Hot Stocks
Microsoft CFO: Q4 another quarter of double-digit top and bottom line growth »

Says commercial bookings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

HBIO

Harvard Bioscience

$1.78

0.03 (1.71%)

17:46
07/18/19
07/18
17:46
07/18/19
17:46
Hot Stocks
Harvard Bioscience names Michael Rossi CFO »

Harvard Bioscience has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$136.29

0.06 (0.04%)

17:43
07/18/19
07/18
17:43
07/18/19
17:43
Hot Stocks
Microsoft CEO seeing growing momentum across every layer of its stack »

Says LinkedIn saw record…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

ISRG

Intuitive Surgical

$536.44

13.25 (2.53%)

17:38
07/18/19
07/18
17:38
07/18/19
17:38
Hot Stocks
Intuitive Surgical falls after Q2 report, despite earnings beat »

Shares of Intuitive are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Aug

  • 09

    Sep

GLD

SPDR Gold Shares

$136.44

1.85 (1.37%)

17:33
07/18/19
07/18
17:33
07/18/19
17:33
Hot Stocks
SPDR Gold Shares holdings rise to 814.62MT from 803.18MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAL

Western Alliance

$44.45

0.74 (1.69%)

17:29
07/18/19
07/18
17:29
07/18/19
17:29
Earnings
Western Alliance reports Q2 EPS 1.19, consensus $1.16 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 06

    Aug

ENB

Enbridge

$36.29

0.17 (0.47%)

17:22
07/18/19
07/18
17:22
07/18/19
17:22
Initiation
Enbridge initiated at Goldman Sachs »

Enbridge initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

SEAS

SeaWorld

$33.81

0.38 (1.14%)

17:21
07/18/19
07/18
17:21
07/18/19
17:21
Periodicals
Travel company Virgin Holidays will end selling tickets to SeaWorld, Sun says »

According to the Sun, …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

IEP

Icahn Enterprises

$75.06

-0.14 (-0.19%)

17:20
07/18/19
07/18
17:20
07/18/19
17:20
Syndicate
Breaking Syndicate news story on Icahn Enterprises »

Icahn Enterprises files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RICK

RCI Hospitality

$16.80

0.08 (0.48%)

17:13
07/18/19
07/18
17:13
07/18/19
17:13
Hot Stocks
RCI Hospitality auditor BDO resigns, company files Nasdaq compliance plan »

RCI Hospitality announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$9.60

-0.06 (-0.62%)

17:03
07/18/19
07/18
17:03
07/18/19
17:03
Earnings
Bright Scholar reports Q3 EPS 16c, two estimates 21c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

ISRG

Intuitive Surgical

$536.44

13.25 (2.53%)

17:03
07/18/19
07/18
17:03
07/18/19
17:03
Hot Stocks
Intuitive Surgical refines FY19 procedure growth view to 16%-17% from 15%-17% »

Still sees FY19 tax rate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Aug

  • 09

    Sep

CUB

Cubic

$66.59

-0.37 (-0.55%)

17:01
07/18/19
07/18
17:01
07/18/19
17:01
Hot Stocks
Cubic receives extension on simulation services contract in Australia »

Cubic Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLRO

ClearOne

$2.27

(0.00%)

16:52
07/18/19
07/18
16:52
07/18/19
16:52
Hot Stocks
Shure files patent infringement suit against ClearOne »

Shure announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISRG

Intuitive Surgical

$536.44

13.25 (2.53%)

16:50
07/18/19
07/18
16:50
07/18/19
16:50
Hot Stocks
Intuitive Surgical says 74% of systems placed in Q2 were da Vinci XIs »

Says team has done a nice…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Aug

  • 09

    Sep

ETN

Eaton

$79.03

-0.36 (-0.45%)

16:49
07/18/19
07/18
16:49
07/18/19
16:49
Hot Stocks
Eaton acquires Innovative Switchgear Solutions »

Eaton announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

ZNGA

Zynga

$6.30

0.07 (1.12%)

16:47
07/18/19
07/18
16:47
07/18/19
16:47
Hot Stocks
Zynga to expand India market with larger space in 'central hub' Bengaluru »

Earlier on Thursday,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 13

    Nov

FNF

Fidelity National

$42.65

-0.045 (-0.11%)

16:43
07/18/19
07/18
16:43
07/18/19
16:43
Recommendations
Fidelity National analyst commentary at Keefe Bruyette »

Fidelity National price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 13

    Nov

AIG

AIG

$55.58

0.2 (0.36%)

16:43
07/18/19
07/18
16:43
07/18/19
16:43
Upgrade
AIG rating change at William Blair »

AIG upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

GOGL

Golden Ocean

$6.63

0.08 (1.22%)

16:42
07/18/19
07/18
16:42
07/18/19
16:42
Syndicate
Breaking Syndicate news story on Golden Ocean »

Golden Ocean files $400M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$361.17

-8.28 (-2.24%)

16:38
07/18/19
07/18
16:38
07/18/19
16:38
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing up over 1% at $366…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

ORCC

Owl Rock

$15.40

(0.00%)

16:38
07/18/19
07/18
16:38
07/18/19
16:38
Initiation
Owl Rock initiated at Compass Point »

Owl Rock initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

FFBC

First Financial Bancorp

$23.90

0.51 (2.18%)

16:37
07/18/19
07/18
16:37
07/18/19
16:37
Hot Stocks
First Financial Bancorp increases dividend 1c to 23c per share »

First Financial Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

KSANF

Kansai Paint

$0.00

(0.00%)

, PPG

PPG

$117.00

0.395 (0.34%)

16:37
07/18/19
07/18
16:37
07/18/19
16:37
Periodicals
Axalta Coating interests rivals PPG and Kansai Paint, Bloomberg reports »

Axalta Coating (AXTA) has…

KSANF

Kansai Paint

$0.00

(0.00%)

PPG

PPG

$117.00

0.395 (0.34%)

AKZOY

AkzoNobel

$0.00

(0.00%)

AXTA

Axalta Coating

$30.40

0.175 (0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 24

    Jul

  • 25

    Jul

  • 05

    Aug

GBCI

Glacier Bancorp

$38.75

0.12 (0.31%)

16:36
07/18/19
07/18
16:36
07/18/19
16:36
Earnings
Glacier Bancorp reports Q2 EPS 61c, consensus 59c »

Reports Q2 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 19

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.